Farmaindustria agrees to sign a protocol in support of the Spanish NHS

3 May 2015

Spanish trade group Farmaindustria’s General Assembly gathered last week in an extraordinary meeting and authorized the signing of a Collaboration Protocol with the Ministries of Finance & Public Administrations, and Health, Social Services and Equality. The protocol is for the sustainability and innovation of the Spanish NHS (National Health Service) in benefit of patients, following steep reductions which have been carried out on public pharma expenditure since 2010.

The said Protocol, which will likely be signed at the end of May, intends to give an answer to the commitments made by Spain before the European Commission with regards to public health care expenditure and to see that the R&D based pharmaceutical industry in Spain performs in line with the economy’s evolution; all of these elements are orientated at providing patients with an adequate and equal access to therapeutic innovations.

Pharma industry commitment

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical